The fact they can trigger antibodies on a stable portion of the virus is impressive. Near the end, it sounds like a multi pronged approach is needed to deal with variations. I’m not an immunologist, but it was pretty light. If they are in trials does that indicate they have a white paper?
"If they are in trials does that indicate they have a white paper?"
I would think they'd have to in order to have the trial. It probably is not for public distribution though.
Clinical trial data gets published online, might be able to find what you're looking for.